Journal of Andrology, Vol 17, Issue 6 659-665, Copyright © 1996 by The American Society of Andrology

JOURNAL ARTICLE

Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation

D. Deperthes, G. Frenette, M. Brillard-Bourdet, L. Bourgeois, F. Gauthier, R. R. Tremblay and J. Y. Dube
Laboratory of Hormonal Bioregulation, CHUL Research Center, Sainte-Foy, Quebec, Canada.

We have recently demonstrated in liquefied human seminal plasma the presence of the novel kallikrein hK2 in association with protein C inhibitor (PCI) as a 75-kDa complex. In the present study, we showed that hK2, immediately after ejaculation, was recovered only in its free form but complex formation with PCI occurred rapidly thereafter and was completed within 10 minutes. That reaction required an enzymatically active kallikrein. In order to determine the patterns of hydrolysis of major seminal vesicle proteins, semenogelins and fibronectin were exposed to hK2 and to hK3 (prostate-specific antigen or PSA) and cleavage sequences were identified by N-terminal sequencing. Free hK2 was able to hydrolyze semenogelins and fibronectin in vitro. Most of cleavage sites were at the carboxyl-side of arginyl residues. Semenogelins were hydrolyzed to a similar extent by catalytic (and similar) concentration of either hK2 or PSA though no common cleavage sites was identified for both proteinases. Unlike semenogelins, fibronectin was hydrolyzed much more efficiently by hK2 than by PSA. These results show that hK2 is enzymatically active during a short period of time after ejaculation, that major seminal vesicle proteins can be the target of this proteolytic activity, and that hK2 and PSA have different substrate specificities.

This article has been cited by other articles:

				N. Emami, D. Deperthes, J. Malm, and E. P. Diamandis Major Role of Human KLK14 in Seminal Clot Liquefaction J. Biol. Chem., July 11, 2008; 283(28): 19561 - 19569. [Abstract] [Full Text] [PDF]

				P. F. Angelo, A. R. Lima, F. M. Alves, S. I. Blaber, I. A. Scarisbrick, M. Blaber, L. Juliano, and M. A. Juliano Substrate Specificity of Human Kallikrein 6: SALT AND GLYCOSAMINOGLYCAN ACTIVATION EFFECTS J. Biol. Chem., February 10, 2006; 281(6): 3116 - 3126. [Abstract] [Full Text] [PDF]

				L.-Y. Luo, S. J.C. Shan, M. B. Elliott, A. Soosaipillai, and E. P. Diamandis Purification and Characterization of Human Kallikrein 11, a Candidate Prostate and Ovarian Cancer Biomarker, from Seminal Plasma Clin. Cancer Res., February 1, 2006; 12(3): 742 - 750. [Abstract] [Full Text] [PDF]

				I. P. Michael, G. Sotiropoulou, G. Pampalakis, A. Magklara, M. Ghosh, G. Wasney, and E. P. Diamandis Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression J. Biol. Chem., April 15, 2005; 280(15): 14628 - 14635. [Abstract] [Full Text] [PDF]

				C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF]

				A. Lundwall, A. Bjartell, A.Y. Olsson, and J. Malm Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues Mol. Hum. Reprod., September 1, 2002; 8(9): 805 - 810. [Abstract] [Full Text] [PDF]

				E. P. Diamandis and G. M. Yousef Human Tissue Kallikreins: A Family of New Cancer Biomarkers Clin. Chem., August 1, 2002; 48(8): 1198 - 1205. [Abstract] [Full Text] [PDF]

				Y. Dong, A. Kaushal, L. Bui, S. Chu, P. J. Fuller, J. Nicklin, H. Samaratunga, and J. A. Clements Human Kallikrein 4 (KLK4) Is Highly Expressed in Serous Ovarian Carcinomas Clin. Cancer Res., August 1, 2001; 7(8): 2363 - 2371. [Abstract] [Full Text] [PDF]

				G. M. Yousef and E. P. Diamandis The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease Endocr. Rev., April 1, 2001; 22(2): 184 - 204. [Abstract] [Full Text]

				C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147. [Abstract] [Full Text]

				C. Becker, T. Piironen, J. Kiviniemi, H. Lilja, and K. Pettersson Sensitive and Specific Immunodetection of Human Glandular Kallikrein 2 in Serum Clin. Chem., February 1, 2000; 46(2): 198 - 206. [Abstract] [Full Text] [PDF]

				C. S. Chan, M. B. Harvey, and J. A. Clements Temporal and Tissue-Specific Expression of Kallikrein (Klk) Genes and Identification of a Novel Klk Messenger Ribonucleic Acid Transcript during Early Development in the Mouse Biol Reprod, September 1, 1999; 61(3): 621 - 628. [Abstract] [Full Text]

				M. S. Saedi, T. M. Hill, K. Kuus-Reichel, A. Kumar, J. Payne, S. D. Mikolajczyk, R. L. Wolfert, and H. G. Rittenhouse The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia Clin. Chem., October 1, 1998; 44(10): 2115 - 2119. [Abstract] [Full Text] [PDF]

				L. Bourgeois, M. Brillard-Bourdet, D. Deperthes, M. A. Juliano, L. Juliano, R. R. Tremblay, J. Y. Dube, and F. Gauthier Serpin-derived Peptide Substrates for Investigating the Substrate Specificity of Human Tissue Kallikreins hK1 and hK2 J. Biol. Chem., November 21, 1997; 272(47): 29590 - 29595. [Abstract] [Full Text] [PDF]